|
|
Article: Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis.
- Article from:
- Business Wire
- Article date:
- July 31, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
First Therapy to Propose Restoration of Neurologic Function as the primary endpoint and the First to Offer the Potential for Elimination of the Autoimmunity Responsible for Multiple Sclerosis
TAMPA, Fla. -- Accentia Biopharmaceuticals Inc. (NASDAQ:ABPI) has filed a preliminary Investigational New Drug (pre-IND) application with the U.S. Food and Drug Administration (FDA) for Revimmune[TM] in the treatment of refractory Multiple Sclerosis (MS). The Company has requested a meeting with the FDA within the next 60 days to discuss a proposed pivotal Phase 3 clinical trial involving approximately 270 patients with relapsing/remitting MS with a primary endpoint of ...
Related newspaper, magazine, and journal articles:
|
|
Article: Findings from Johns Hopkins University broaden ...
Immunotherapy Weekly;
May 27, 2009 ;
700+ words
... ... colleagues, Johns Hopkins University ... disability in multiple sclerosis and have implications ... dysfunction in multiple sclerosis and column ... Zackowski, Johns Hopkins University ... Resonance, Multiple Sclerosis, Neuroimmunology ...
|
|